Lab studies suggest that the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providing antibody protection against the 501.V2 variant of the disease, which is most prevalent in South Africa.
Lab studies suggest the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in protecting against the 501.V2 variant of the disease, most prevalent in South Africa. [https:--www.theguardian.com-world-2021-feb-18-south-african-covid-variant-may-cut-pfizer-vaccine-protection-by-two-thirds (The Guardian)]Variants of SARS-CoV-2
Lab studies suggest the Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providingantibodyprotection against the 501.V2 variant of the disease, most prevalent in South Africa.
Lab studies suggest thatthe Pfizer–BioNTech and Moderna COVID-19 vaccines are significantly less effective in providing antibody protection against the 501.V2 variant of the disease,whichis most prevalent in South Africa.
